Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting

Noveris shareholders backed all 2026 meeting resolutions, including board elections, auditor appointment, incentive plan approval and revised quorum rules.

Rhea-AI Summary

Noveris Health Sciences (MYCOF) reported that all resolutions at its September 4, 2026 annual general and special meeting were approved, with 21,697,593 common shares represented, or about 37.06% of shares entitled to vote.

Shareholders set the number of directors at three, with over 99.9% of votes cast in favour. Jason Birmingham, Michael Callas and Peter Field were each elected as directors, receiving approximately 99.98% votes for and 0.02% withheld. HDCPA Professional Corporation was appointed auditor, with 99.98% of votes for. The Amended and Restated Omnibus Long-Term Incentive Plan was approved with 99.89% support, and a special resolution to amend the Articles to change quorum requirements passed with 99.94% of votes for.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting").

A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the Meeting.

All resolutions presented to shareholders at the Meeting were approved.

Number of Directors

Shareholders approved setting the number of directors of the Company at three.

	Votes	Percentage
For	21,691,077	99.97%
Against	6,516	0.03%

 

Election of Directors

Shareholders elected Jason Birmingham, Michael Callas and Peter Field as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed.

Nominee	Votes For	% For	Votes Withheld	% Withheld
Jason Birmingham	21,693,551	99.98%	4,042	0.02%
Michael Callas	21,692,406	99.98%	5,187	0.02%
Peter Field	21,694,050	99.98%	3,543	0.02%

 

Appointment of Auditor

Shareholders approved the appointment of HDCPA Professional Corporation as auditor of the Company for the ensuing year and authorized the directors to fix the auditor's remuneration.

	Votes	Percentage
For	21,693,250	99.98%
Withheld	4,343	0.02%

 

Omnibus Long-Term Incentive Plan

Shareholders approved the Company's Amended and Restated Omnibus Long-Term Incentive Plan.

	Votes	Percentage
For	21,674,601	99.89%
Against	22,992	0.11%

 

Amendment to Articles

Shareholders approved the special resolution authorizing an amendment to the Company's Articles to change the quorum requirements.

	Votes	Percentage
For	21,683,976	99.94%
Against	13,617	0.06%

 

The Company thanks its shareholders for their participation in the Meeting and their continued support.

About Noveris Health Sciences Inc.

Noveris Health Sciences Inc. is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. Additional information concerning the Company is available under its profile on SEDAR+ at www.sedarplus.ca and at www.noveris.health.

On behalf of the Board of Directors
NOVERIS HEALTH SCIENCES INC.
Jason Birmingham, Chief Executive Officer

For Further Information
Tel: +1 778-900-NVRS (6877)
Email: fair@noveris.health
Web: www.noveris.health

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313698